MMS Holdings Inc.

What MMS Holdings Inc. does

MMS Holdings Inc. is a privately held, founder-owned data-focused contract research organization (CRO) headquartered in Canton, Michigan, founded in 2006 by Dr. Uma Sharma. The company delivers clinical research services to pharmaceutical and biotech sponsors across the development lifecycle — from pre-IND strategic consulting through regulatory submissions, biometrics, pharmacovigilance and safety, REMS, and post-approval support — with documented depth in complex indications including oncology, rare diseases, CNS disorders, and psychedelic-assisted therapies. Revenue is generated primarily through project-based professional services contracts plus Functional Service Provider (FSP) arrangements where MMS teams embed within sponsor organizations; proprietary technology platforms are offered largely as integrated components of service engagements rather than as standalone products. Pricing is quote-based for enterprise clients and is not publicly disclosed.

Name

MMS Holdings Inc.

Legal name

MMS Holdings Inc.

Website

https://mmsholdings.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

501–1,000 employees

Short description

MMS Holdings is a privately held, data-focused contract research organization serving pharmaceutical and biotech sponsors with regulatory submissions, biometrics, pharmacovigilance, and clinical trial design services, supported by four proprietary AI-powered platforms, operating across four continents.

Ownership category

akta.pro rank

Product category

Clinical Research Organization (CRO) Services

NAICS

Management Consulting Services (54161), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

Keywords

• Clinical research services
• Biometrics solutions
• Pharmacovigilance services
• Regulatory submissions support
• Clinical trial simulation

Headquarters

HQ city

Canton

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: MMS provides comprehensive CRO services including regulatory submissions, biometrics, pharmacovigilance, and strategic consulting on a project or FSP basis. Revenue is generated through service contracts with pharmaceutical and biotech sponsors.
2. Technology Licensing: Proprietary platforms including KerusCloud, Datacise, PVantage, and Automatiqc may be offered as part of integrated service packages or potentially as standalone technology solutions.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

MMS Holdings Inc. is a data-focused clinical research organization that provides pharmaceutical and biotech sponsors with regulatory submissions, biometrics, pharmacovigilance, safety/risk management, REMS, and strategic consulting services on a project or Functional Service Provider basis. The firm layers proprietary cloud and AI platforms—KerusCloud®, Datacise®, PVantage™, and Automatiqc®—over its service offerings to support clinical trial simulation, real-time data aggregation and analytics, case processing automation, and AI-assisted medical writing.

Product overview

MMS Holdings is a data-focused Clinical Research Organization (CRO) offering a platform-plus-services architecture. Its proprietary technology portfolio includes four core products: KerusCloud® (clinical trial simulation platform), Datacise® (data visualization and analytics platform with CURATE/ANALYZE/EXPLORE modules), Automatiqc® (medical writing automation), and PVantage™ (pharmacovigilance case management). These technology platforms are integrated with comprehensive CRO services spanning strategic consulting, full-service biometrics, regulatory submissions, REMS solutions, safety & risk management, therapeutic expertise, FSP partnerships, and CRO rescue solutions. The company operates globally across four continents with expertise in oncology, rare diseases, psychedelics, and CNS disorders.

Differentiator

Problem solved

Functional benefit

Brands

• KerusCloud®: Advanced AI-powered clinical trial simulation software that enables modeling and analysis of virtual trial scenarios, optimizing endpoints, recruitment strategies, and estimand frameworks before real studies begin.
• Datacise®
• PVantage™
• Automatiqc®

Products and services

• KerusCloud®

Quantifiable outcome

• Up to 41% improvement in probability of trial success using KerusCloud
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration16 records

AI capability10 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and notable.

• ExploristicscoreStrategic or Co-development Partner · 1 February 2026In February 2026, MMS Holdings acquired Exploristics, a leading Statistical analytics solutions provider known for innovation in clinical trial design and simulation. This acquisition brought the power of KerusCloud to MMS clients.
• Oracle Health SciencesnotableTechnology or IntegrationOracle Health Sciences and MMS collaborated to deliver a complex database build for an oncology sponsor, demonstrating MMS's technical capabilities and integration with major healthcare technology platforms.
• Friends of Cancer ResearchnotableStrategic or Co-development PartnerMMS was selected by Friends of Cancer Research to support the development of practical decision frameworks to inform interpretation of interim overall survival data in oncology clinical trials, contributing to advancing cancer research methodology.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cato SMS: Specialized CRO with strong pharmacovigilance, regulatory, and drug safety offerings serving small/mid-sized pharma. Comparable to MMS in the safety/risk management and regulatory submissions segments and in customer profile.
• Worldwide Clinical Trials: Mid-market scientific CRO focused on complex therapeutic areas including CNS, rare disease, and oncology. Comparable to MMS in scale, therapeutic specialization, and emphasis on biometric/regulatory expertise rather than pure full-service volume.
• Premier Research: Specialty CRO focused on biotech and emerging pharma with deep expertise in rare disease, oncology, and CNS. Comparable to MMS in mid-market positioning, therapeutic-area specialization, and biotech-heavy customer base.
• Veristat: Specialist biostatistics, regulatory, and clinical services CRO focused on complex submissions. Closely comparable to MMS's biometrics, regulatory submissions, and data-led model targeting small/mid-sized biotech sponsors.
• Medpace Holdings: Mid-sized, scientifically-focused full-service CRO with strong biometrics, regulatory affairs, and biostatistics capabilities. Highly comparable to MMS as a specialized, mid-tier CRO with an integrated technology platform approach serving pharma/biotech sponsors globally.

Broad incumbents

• IQVIA: Largest global CRO and life sciences technology provider with comprehensive biometrics, regulatory, and AI-driven analytics. Direct overlap with MMS in clinical research services, but at vastly larger scale and broader service portfolio.
• Labcorp Drug Development (Fortrea): Spun off from Labcorp as a leading global CRO with comprehensive clinical, biometrics, and lab services. Comparable in offering mix (especially central labs + biometrics + regulatory), far larger in scale and geographic reach than MMS.
• ICON plc: Top-3 global full-service CRO with broad therapeutic coverage, technology platforms (e.g., Accellacare), and deep regulatory/biometrics. Direct overlap with MMS across nearly every service line but at much greater scale and global breadth.
• Parexel International: Large global CRO with deep regulatory, biostatistics, and clinical operations. Direct overlap on regulatory submissions and biometrics, with comparable mid-size specialist-CRO positioning, though significantly larger in scale.

Emerging players

• Exploristics: Statistical analytics and clinical trial simulation specialist whose KerusCloud platform was recently acquired by MMS. Listed as comparable due to overlapping biostatistics and simulation capabilities now embedded in MMS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mms-holdings-inc-
• Xx.com/mmsholdings
• Facebookfacebook.com/mmsholdings

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MMS Holdings Inc.